Substance P (TFA)

Substance P (TFA)

• CAS Number: 148470-19-3
• UNSPSC Description: Substance P TFA (Neurokinin P TFA) is a neuropeptide, acting as a neurotransmitter and as a neuromodulator in the CNS. The endogenous receptor for substance P is neurokinin 1 receptor (NK1-receptor, NK1R)[1].
• Target Antigen: Endogenous Metabolite; Neurokinin Receptor
• Type: Peptides
• Related Pathways: GPCR/G Protein;Metabolic Enzyme/Protease;Neuronal Signaling
• Applications: Neuroscience-Neuromodulation
• Field of Research: Endocrinology; Neurological Disease; Cancer
• Assay Protocol: https://www.medchemexpress.com/substance-p-tfa.html
• Purity: 95.16
• Solubility: H2O : 100 mg/mL (ultrasonic)
• Smiles: OC(C(F)(F)F)=O.O=C([C@H]1N(CCC1)C([C@@H](N)CCCNC(N)=N)=O)N[C@@H](CCCCN)C(N2[C@@H](CCC2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@H](C(NCC(N[C@@H](CC(C)C)C(N[C@H](C(N)=O)CCSC)=O)=O)=O)CC3=CC=CC=C3)=O)CC4=CC=CC=C4)=O)=O)=O)=O
• Molecular Weight: 1461.65
• References & Citations: [1]Grady EF, et al. Delineation of the endocytic pathway of substance P and its seven-transmembrane domain NK1 receptor. Mol Biol Cell. 1995 May;6(5):509-24.|[2]Zhang L, et al. MiR-34b/c-5p and the neurokinin-1 receptor regulate breast cancer cell proliferation and apoptosis. Cell Prolif. 2018 Oct 17:e12527.Mol Med Rep. December 13, 2021.|Authorea. 2023 Aug 14.|Cell Discov. 2023 Jun 30;9(1):66.|Cell Prolif. 2019 Jan;52(1):e12527.|Chin J Comp Med. May 2018,Vol. 28. No. 5|Eur J Pharmacol. 2023 Jul 6;175902.|Free Radic Biol Med. 2023 Oct 5;209(Pt 1):1-8.|Immunol Lett. 2024 Oct 10:106934.|Int J Biol Sci. 2024 Apr 22;20(7):2507-2531.|iScience. 2023 Apr 13.|J Am Soc Mass Spectrom. 2020 Jul 5.|J Headache Pain. 2024 Aug 28;25(1):141.|J Immunol Res. 2022 May 12;2022:5582811.|J Invest Dermatol. 2022 Nov 18;S0022-202X(22)02770-1.|Mol Biol Rep. 2022 Jan 16.|Prog Neurobiol. 2021 Mar 22;102041.|Research Square Preprint. 2021 Dec.|Research Square Preprint. 2021 Jul.|Research Square Preprint. 2021 Sep.
• Shipping Conditions: Blue Ice
• Storage Conditions: -80°C, 2 years; -20°C, 1 year (Powder, stored under nitrogen, away from moisture)
• Clinical Information: No Development Reported